Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System
GLP-1 and dual-incretin agents did not show disproportionality signals for suicidal ideation or suicide attempt. A statistically significant disproportionality signal for completed suicide was observed for liraglutide; however, this estimate was based on few cases and displayed wide confidence intervals, warranting cautious interpretation. These findings support an overall neutral psychiatric safety profile for incretin-based therapies while underscoring the need for continued monitoring of rare events such as completed suicide.
Authors
- Diego Rodríguez‐Penas
- Begoña Cardeso-Paredes
- JR González-Juanatey
- Marta Ribeiro-Ferreiro
- Moises Rodriguez-Mañero
- Ángel Salgado-Barreira
- Jose Seijas-Amigo
Institutions
- Universidade de Santiago de Compostela (ES)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Centro de Investigación Biomédica en Red (ES)
- Instituto de Investigación Sanitaria de Santiago (ES)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES)
Publication Details
- Journal
- International Journal of Clinical Pharmacy
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1007/s11096-026-02099-y
- Citations
- 1
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 33.63
Funders
- Fundación Instituto de Investigación Sanitaria de Santiago de Compostela
- Instituto de Investigación Sanitaria de Santiago de Compostela
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares
- U.S. Food and Drug Administration